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cancer, and report here the results of our preplanned safety 
analysis.
Methods Patients aged 20–79 years with curatively resected 
stage III colon cancer were randomly assigned to receive 8 
cycles (6 months) or 16 cycles (12 months) of capecitabine 
(2500 mg/m2/day on days 1–14 of each 21-day cycle). Treat-
ment exposure and adverse events (AEs) were evaluated.
Abstract 
Background Six months of adjuvant chemotherapy is 
regarded as the standard of care for patients with stage 
III colon cancer. However, whether longer treatment can 
improve prognosis has not been fully investigated. We 
conducted a phase III study comparing 6 and 12 months 
of adjuvant capecitabine chemotherapy for stage III colon 
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Results A total of 1304 patients (642 and 636 in the 
6-month and 12-month groups, respectively) were ana-
lyzed. The most common AE was hand-foot syndrome 
(HFS). HFS, leukocytopenia, neutropenia, and hyper-
bilirubinemia (any grade) occurred more frequently in the 
12-month group than in the 6-month group. HFS was the 
only grade ≥3 AE to have a significantly higher incidence 
in the 12-month group (23 vs 17%, p = 0.011). The com-
pletion rate for 8 cycles was 72% in both groups, while that 
for 16 cycles was 46% in the 12-month group. HFS was the 
most common AE requiring dose reduction and treatment 
discontinuation.
Conclusions Twelve months of adjuvant capecitabine dem-
onstrated a higher cumulative incidence of HFS compared 
to the standard 6-month treatment period, while toxicities 
after 12 months of capecitabine were clinically acceptable.
Trial registration UMIN-CTR, UMIN000001367.
Keywords Colon cancer · Adjuvant chemotherapy · 
Capecitabine · Treatment duration · Adverse events · Hand-
foot syndrome
Introduction
Colorectal cancer (CRC) is one of the most common can-
cers in Japan, with over 147,000 new cases expected in 
2016 [1]. Postoperative adjuvant chemotherapy for patients 
with stage III CRC is the internationally accepted standard 
of care to improve patient survival.
In the mid-1990s, based on the results of several stud-
ies [2, 3], a 6-month course of intravenous 5-fluorouracil 
(5-FU) plus leucovorin (LV) came to be regarded as the 
standard regimen of adjuvant chemotherapy for colon can-
cer. From the following studies investigating oral FUs (such 
as tegafur-uracil [UFT] plus LV, capecitabine), and oxalipl-
atin-containing regimens (i.e., FOLFOX and CapeOX) as 
adjuvant chemotherapy for colon cancer, Western countries 
selected 6 months as the standard treatment duration [4–7]. 
Therefore, 6 months of adjuvant chemotherapy has been 
recognized as the global clinical standard.
On the other hand, by analyzing the data of >20,800 
patients from 18 randomized controlled studies (RCTs) 
in the Adjuvant Colon Cancer Endpoints (ACCENT) 
database, Sargent et al. [8] demonstrated that the risk of 
stage II-III CRC recurrence was highest between 12 and 
18 months after surgery and proposed that decreasing 
the recurrence risk at 12–18 months after surgery might 
improve survival. The results of a meta-analysis of three 
studies (JFMC 7-1, 7-2, and 15) by Hamada et al. [9], 
investigating the risk of recurrence in 2848 patients with 
curatively resected colon cancer followed by 1-year admin-
istration of oral FUs, strongly suggested that 12 months of 
oral FU drugs might translate the short-term (1–2 years) 
reduction in the risk of recurrence into a delayed advantage 
in overall survival (OS).
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Those findings suggest that extending adjuvant oral FU 
therapy from 6 to 12 months might be able to improve 
prognosis. However, whether 12 months of adjuvant 
chemotherapy can decrease the peak of recurrence risk 
between 12 and 18 months postoperatively and improve 
survival has not been investigated by RCT. Therefore, we 
conducted a phase III study, JFMC37-0801 (UMIN-CTR; 
UMIN000001367), to compare 6 and 12 months of adju-
vant chemotherapy using capecitabine (Chugai Pharmaceu-
tical Co. Ltd., Tokyo, Japan), the most commonly used oral 
FU for CRC worldwide, in patients with stage III colon 
cancer.
The safety of adjuvant capecitabine for colon cancer has 
not been studied in a large sample of Japanese patients, 
even though adjuvant capecitabine is widely used clini-
cally for CRC in Japan. Furthermore, it is unclear whether 
a longer treatment period might influence the incidence 
and severity of adverse events (AEs). We therefore report 
the results of a preplanned safety analysis, to increase the 
safety of capecitabine use in clinical practice.
Patients and methods
Enrollment and assignment
This study was conducted in accordance with the Decla-
ration of Helsinki and the Ethical Guidelines for Clinical 
Research in Japan, and was approved by the Institutional 
Review Boards of each participating institute. Written 
informed consent was obtained from all patients before 
enrollment, and eligible patients were centrally registered.
The main eligibility criteria were (1) histologically 
confirmed stage III colon adenocarcinoma; (2) curatively 
resected with extended lymph node dissection (D2 or D3 
in the Japanese Classification of Colorectal Carcinoma, 8th 
edition) [10]; (3) aged 20–79 years; (4) Eastern Coopera-
tive Oncology Group performance status (ECOG-PS) of 0 
to 1; (5) no prior chemotherapy or radiotherapy for CRC; 
(6) no other active malignancies; (7) adequate oral intake; 
(8) preserved major organ functions, and (9) no uncontrol-
lable severe infection.
Randomization and masking
After confirming eligibility, enrolled patients were ran-
domly assigned to receive either 8 cycles (6 months) or 16 
cycles (12 months) of capecitabine at the central registra-
tion center, using a minimization method, with stratifica-
tion by lymph node metastasis (N1 or N2-3 in the Japanese 
Classification of Colorectal Carcinoma, 8th edition) [10] 
and institution. The assigned treatment arm was not blinded 
from both investigators and patients.
Protocol treatment
Capecitabine was orally given at a dose of 1250 mg/m2 
twice daily after meals for 14 consecutive days, followed 
by a 7-day rest. This 3-week treatment comprised 1 cycle. 
The control group (6M group) received 8 cycles and the 
study group (12M group) received 16 cycles. After com-
pleting the scheduled treatment, each group was switched 
to the follow-up schedule defined in the protocol, with-
out any treatment until confirmation of metastasis or 
recurrence.
The assigned treatment was started within 8 weeks after 
surgery. During treatment, clinical findings and laboratory 
values were evaluated at least every 3 weeks. Evaluation 
at the beginning of each cycle was mandatory. Patients 
received treatment if they fulfilled the following crite-
ria—leukocytes ≥3000/mm3, neutrophils ≥1500/mm3, 
platelets ≥75,000/mm3, aspartate aminotransferase (AST) 
and alanine aminotransferase (ALT) ≤2.5 × upper limit 
of normal (ULN), total bilirubin ≤1.5 × ULN, creatinine 
<1.5 × ULN, and no higher than grade 1 non-hematologic 
toxicities (i.e., anorexia, nausea, vomiting, and diarrhea). If 
the criteria for starting/continuing treatment were not ful-
filled, treatment was postponed or temporarily suspended 
until AEs had improved sufficiently to meet the criteria. 
Supportive care including antiemetics, antidiarrheal drugs, 
liver supporting therapy (e.g., ursodeoxycholic acid), gran-
ulocyte colony-stimulating factor, oral vitamin B6, and 
external use of hydrating cream and steroids were allowed 
when physicians considered necessary.
Depending upon the severity of the AEs at the time of 
treatment suspension, the dose of capecitabine was reduced 
in accordance with the protocol. When a grade 2 AE 
developed the first time, treatment with capecitabine was 
suspended until the AE improved to grade ≤1, and then 
resumed at the same dose. If a grade 2 AE occurred twice 
or if a grade 3 AE occurred, the dose of capecitabine was 
reduced by 25%. The minimum dose was 50% of the initial 
dose recommended in the protocol.
The treatment was discontinued if (1) recurrence or 
other malignancies developed; (2) a grade 4 AE occurred; 
(3) treatment could not be resumed within 21 days after its 
postponement or temporary suspension; (4) further dose 
reduction was necessary even after the specified dose was 
reduced by two levels (−50%); (5) the physician judged 
that the protocol treatment was too difficult to continue; (6) 
the patient requested discontinuation of the treatment, and 
(7) the patient withdrew their informed consent.
Data collection
Treatment information, such as the daily dose and the num-
ber of days of administration in each cycle, was collected 
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from the case report forms of each patient. The relative 
dose intensity (RDI) for each cycle was defined as the 
ratio of the actual cumulative dose to the protocol-speci-
fied cumulative dose in each cycle. Completion rate of the 
protocol treatment was defined as the ratio of the number 
of patients who completed 8 or 16 cycles of capecitabine 
treatment to the number of patients included the safety 
analysis set of each treatment group.
The type and severity of AEs in each cycle were evalu-
ated according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events version 3.0. 
The most severe grade of each AE during each cycle was 
reported.
Statistical analysis
All statistical analyses were performed using SAS software 
version 9.2 (SAS Institute, Cary, NC, USA). Descriptive 
statistics such as means, standard deviations, and medians 
were calculated. The chi-squared test was used to compare 
the incidence of AEs between the treatment groups. A p 
value <0.05 was considered significant.
Results
Patient characteristics
From September 2008 through December 2009, a total 
of 1304 patients were enrolled from 333 institutes in 
Japan, and randomized. Of these, 1278 patients (642 in 
the 6M group and 636 in the 12M group) who received 
capecitabine treatment were included in the safety analy-
sis set (Fig. 1). All data for the analysis were finalized in 
March of 2016.
Patient characteristics are shown in Table 1. Median 
age at enrollment was 65 years (range 23–79); 53.7% were 
male, and 96.1% were PS 0. Baseline characteristics of the 
two treatment groups were well balanced.
Treatment duration
The median number of administered cycles was 8 in the 
6M group and 15 in the 12M group. The completion rate 
for 8 cycles of capecitabine was similar in the 6M group 
(71.5%) and 12M group (71.7%). The final 16-cycle com-
pletion rate in the 12M group was 46.1% (Table 2). In both 
treatment groups, treatment discontinuation occurred at 
a similar frequency during both the first and last 8 cycles. 
Among 417 patients in the 12M group who began the 9th 
cycle, 293 (70.3%) completed 16 cycles (Table 2).
Reasons for treatment discontinuation
In all, 183 patients (28.5%) and 343 patients (53.9%) in 
the 6M group and 12M group, respectively, dropped out 
from the protocol treatment. Their reasons for treatment 
discontinuation are listed in Table 3. The distribution of 
patients according to reason for discontinuation was simi-
lar between the two groups. AEs (listed in the protocol as 
treatment discontinuation criteria) or physician’s judgment 
were the most common reasons for discontinuation, and 
occurred in 50.3, 53.0, and 34.7% of discontinued patients 
during cycles 1–8 in the 6M group, and cycles 1–8 and 
Fig. 1  CONSORT diagram
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Table 1  Patient characteristics
ECOG Eastern Cooperative Oncology Group, C cecum, A ascending colon, T transverse colon, D descending colon, S sigmoid colon, LN lymph 
node
N1: Metastasis in 1–3 pericolic/perirectal LNs or intermediate LNs (LNs along the colic artery)
N2: Metastasis in ≥4 pericolic/perirectal or intermediate LNs
N3: Metastasis in LNs around the origin of the ileocolic, right colic, middle colic, or inferior mesenteric artery
D2: Complete dissection of pericolic/perirectal and intermediate LNs
D3: Complete dissection of all regional LNs
a Defined in the Japanese Classification of Colorectal Carcinoma 8th edition, published by the Japanese Society for Cancer of the Colon and 
Rectum (JSCCR) [10]
6M group (n = 642) 12M group (n = 636)
n (%) n (%)
Age
 Median [range] 65 [23–79] 65 [34–79]
Gender
 Male 347 (54.0%) 339 (53.3%)
 Female 295 (46.0%) 297 (46.7%)
ECOG performance status
 0 611 (95.2%) 617 (97.0%)
 1 31 (4.8%) 19 (3.0%)
Creatinine clearance (mL/min)
 Median [range] 76.6 [35.1–350.4] 78.1 [39.2–176.3]
Body surface area (m2)
 Median [range] 1.59 [1.06–2.42] 1.56 [1.10–2.14]
 <1.33 (dose 3000 mg/body/day) 41 (6.4%) 48 (7.5%)
 ≥1.33 to <1.57 (dose 3600 mg/body/day) 262 (40.8%) 272 (42.8%)
 ≥1.57 to <1.81 (dose 4200 mg/body/day) 274 (42.7%) 261 (41.0%)
 ≥1.81 (dose 4800 mg/body/day) 65 (10.1%) 55 (8.6%)
Tumor location
 Right-sided colon (C, A, T) 261 (40.6%) 258 (40.6%)
 Left-sided colon (D, S) 247 (38.5%) 247 (38.8%)
 Rectosigmoid colon 134 (20.9%) 131 (20.6%)
Depth of tumor invasion (TNM 7th)
 T1 44 (6.9%) 45 (7.1%)
 T2 54 (8.4%) 52 (8.2%)
 T3 360 (56.1%) 355 (55.8%)
 T4 184 (28.7%) 184 (28.9%)
LN metastasis (JSCCR classificationa)
 N1 491 (76.5%) 486 (76.4%)
 N2 120 (18.7%) 121 (19.0%)
 N3 31 (4.8%) 29 (4.6%)
Stage (TNM 7th)
 IIIA 91 (14.2%) 93 (14.6%)
 IIIB 455 (70.9%) 450 (70.8%)
 IIIC 96 (15.0%) 93 (14.6%)
Scope of LN dissection (JSCCR classificationa)
 D2 129 (20.1%) 133 (20.9%)
 D3 513 (79.9%) 503 (79.1%)
Surgical approach
 Open (conventional) 371 (57.8%) 388 (61.0%)
 Laparoscopic 271 (42.2%) 248 (39.0%)
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9–16 in the 12M group, respectively. Approximately 14.8, 
17.4, and 15.3% of discontinued patients, respectively, 
requested to discontinue the treatment because of AEs not 
mentioned in the discontinuation criteria.
Types of AEs leading to treatment discontinuation are 
presented in Table 4. Distribution of patients according to 
cause of discontinuation was similar between the 6M and 
12M group, and between cycles 1–8 and cycles 9–16 in 
the 12M group. HFS was the most common discontinua-
tion criteria-specified AE leading to discontinuation or the 
basis for physician’s judgment to discontinue treatment. 
The proportion of patients requesting treatment discontinu-
ation because of HFS was similar to that requesting treat-
ment discontinuation because of other non-hematologic 
Table 2  Treatment 
discontinuation by cycle
6M group (n = 642) 12M group 
(n = 636)
n (%) n (%)
No. of patients discontinued
 During cycle 1 23 (3.6%) 25 (3.9%)
 During cycle 2 21 (3.3%) 32 (5.0%)
 During cycle 3 37 (5.8%) 33 (5.2%)
 During cycle 4 21 (3.3%) 26 (4.1%)
 During cycle 5 23 (3.6%) 20 (3.1%)
 During cycle 6 21 (3.3%) 13 (2.0%)
 During cycle 7 23 (3.6%) 28 (4.4%)
 During cycle 8 14 (2.2%) 42 (6.6%)
 During cycle 9 – – 19 (3.0%)
 During cycle 10 – – 15 (2.4%)
 During cycle 11 – – 16 (2.5%)
 During cycle 12 – – 10 (1.6%)
 During cycle 13 – – 14 (2.2%)
 During cycle 14 – – 14 (2.2%)
 During cycle 15 – – 25 (3.9%)
 During cycle 16 – – 11 (1.7%)
No. of patients completed 8 cycles of capecitabine 459 (71.5%) 456 (71.7%)
No. of patients completed 16 cycles of capecitabine – – 293 (46.1%)
Table 3  Reasons for treatment discontinuation
6M group (n = 642) 12M group (n = 636)
n (%) During cycles 1–8 During cycles 
9–16
n (%) n (%)
No. of patients with discontinuation 183 (100%) 219 (100%) 124 (100%)
Reasons for discontinuation
Oncologic events
 Recurrences 17 (9.3%) 12 (5.5%) 12 (9.7%)
 Second cancers 3 (1.6%) 2 (0.9%) 1 (0.8%)
Adverse events (AEs)
 AEs (listed on the discontinuation criteria) or physician’s judgement 92 (50.3%) 116 (53.0%) 43 (34.7%)
 Patient’s request due to AEs not mentioned in the discontinuation criteria 27 (14.8%) 38 (17.4%) 19 (15.3%)
Others
 Aggravation of comorbidities 5 (2.7%) 9 (4.1%) 8 (6.5%)
 Patient’s request due to non-medical reasons 16 (8.7%) 35 (16.0%) 20 (16.1%)
 Others 23 (12.6%) 7 (3.2%) 21 (16.9%)
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toxicities. Overall, HFS was the leading AE for treatment 
discontinuation.
Dose modification
The dose was reduced 314 times in 241 patients (37.5%) in the 
6M group and 477 times in 306 patients (48.1%) in the 12M 
group. In the 12M group, the proportion of patients with dose 
reduction was lower during cycles 9–16 than during cycles 
1–8 (26.1 vs 40.4%) (Table 5). The most common reason for 
dose reduction was HFS, which occurred 191 times (60.8%) 
in the 6M group and 290 times (60.8%) in the 12M group.
The RDI for each cycle is shown in Fig. 2. RDI 
decreased gradually with each successive treatment cycle, 
and was ≥60% in 424 patients (66.0%) in the 6M group at 
cycle 8, 397 patients (62.4%) in the 12M group at cycle 8, 
and 222 patients (34.9%) in the 12M group at cycle 16. The 
mean RDI for the entire treatment period and all patients, 
including those who discontinued prematurely, was 79.5% 
in the 6M group and 61.3% in the 12M group (median was 
89.6 and 65.4%, respectively).
Safety profile (6M group vs 12M group)
A total of 589 patients (91.7%) in the 6M group and 602 
patients (94.7%) in the 12M group experienced AEs 
(p = 0.051). Moreover, 158 patients (24.6%) in the 6M 
group and 197 patients (31.0%) in the 12M group experi-
enced grade ≥3 AEs (p = 0.013). The incidence of major 
AEs (by worst grade throughout the treatment period) is 
shown in Table 6. The most common AE was HFS; the 
incidence of grade ≥3 HFS was 16.8 and 22.6% in the 
6M group and 12M group, respectively. Other grade ≥3 
AEs with ≥1% incidence included neutropenia, diarrhea, 
fatigue, and anorexia. There was no treatment-related death 
in the study.
AEs (any grade) with a higher incidence in the 12M 
group than in the 6M group included leukocytopenia 
(25.6 vs 19.2%, p = 0.007), neutropenia (20.6 vs 15.4%, 
p = 0.020), hyperbilirubinemia (39.2 vs 31.2%, p = 0.003), 
and HFS (77.0 vs 72.0%, p = 0.043). HFS was the only 
grade ≥3 AE to occur more frequently in the 12M group 
than in the 6M group (22.6 vs 16.8%, p = 0.011).
Table 4  Adverse events causing discontinuation of treatment
AEs adverse events
a Not including hand-foot syndrome
6M group (n = 642) 12M group (n = 636)
During cycles 1–8 During cycles 9–16






AEs (listed on the discontinuation criteria) or 
physician’s judgement
Hematologic toxicities 18 (14.6%) 25 (15.6%) 9 (13.8%)
Abnormal liver function 18 (14.6%) 22 (15.8%) 8 (12.3%)
Hand-foot syndrome 38 (30.9%) 60 (37.5%) 19 (29.2%)
Non-hematologic toxicitiesa 18 (14.6%) 11 (6.9%) 7 (10.8%)
Patient’s request due to AEs not mentioned in the 
discontinuation criteria
Hematologic toxicities 2 (1.6%) 2 (1.3%) 1 (1.5%)
Abnormal liver function 0 (0%) 0 (0%) 0 (0%)
Hand-foot syndrome 11 (8.9%) 21 (13.1%) 10 (15.4%)
Non-hematologic toxicities* 18 (14.6%) 18 (11.3%) 9 (13.8%)
Unknown 0 (0%) 1 (0.6%) 2 (3.1%)
Table 5  Dose reduction
Dose reduction 6M group (n = 642) 12M group (n = 636)
Overall (n = 636) During cycles 1–8 (n = 636) During cycles 9–16 (n = 417)
n (%) n (%) n (%) n (%)
(−) 401 (62.5%) 330 (51.9%) 379 (59.6%) 308 (73.9%)
(+) 241 (37.5%) 306 (48.1%) 257 (40.4%) 109 (26.1%)
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Safety profile (cycles 1–8 vs cycles 9–16)
A comparison of the incidence of AEs between the first 8 
cycles and the second 8 cycles in the 12M group (Table 7) 
revealed no difference in the incidence of hematologic tox-
icities. Another non-hematological AEs (any grade) includ-
ing anorexia (9.1 vs 18.4%, p < 0.001), nausea (4.1 vs 
12.4%, p < 0.001), stomatitis (10.6 vs 18.9%, p < 0.001), 
diarrhea (6.7 vs 11.6%, p = 0.011), fatigue (7.9 vs 13.1%, 
p = 0.012), and vomiting (1.7 vs 4.2%, p = 0.034) were 
lower in cycles 9–16 than in cycles 1–8. This shows that 
the incidence of gastrointestinal toxicities was lower dur-
ing the later period of treatment while that of hematologic 
toxicities remained fairly constant over the entire treat-
ment course. HFS was the only grade ≥3 AE with a sig-
nificantly lower incidence in the later period (8.6 vs 19.0%, 
p < 0.001). However, the incidence of grade ≥3 HFS 
(8.6%) was by far the highest of any grade ≥3 AE occur-
ring during cycles 9–16.
The cumulative incidence of grade ≥1, grade ≥2, and 
grade ≥3 HFS by treatment group is shown in Fig. 3. The 
rise in cumulative onset of HFS during cycles 1–8 was 
quite similar between the 6M group and 12M group. In the 
12M group, the rise in cumulative onset was gradual and 
constant even during cycles 9–16.
Discussion
We compared the treatment details and AE profile after 6 
and 12 months of adjuvant capecitabine in 1278 Japanese 
patients with stage III colon cancer. This is the first pro-
spective RCT data demonstrating the safety of adjuvant 
capecitabine in a large sample of Japanese patients.
The most common AE was HFS, a characteristic toxic 
reaction to capecitabine; 72.0 and 77.0% of patients expe-
rienced grade ≥1 HFS, and 16.8 and 22.6% experienced 
grade ≥3 HFS in the 6M group and 12M group, respec-
tively. The incidences of other AEs were relatively low 
overall and acceptable.
A comparison of the AE profile between our study and 
the X-ACT trial [5], a pivotal study of adjuvant capecit-
abine for colon cancer patients (Table 8), found no differ-
ence in the incidence of grade ≥3 HFS between Japanese 
Fig. 2  Relative dose intensity 
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Table 6  Incidence of adverse events by the treatment group
AST aspartate aminotransferase, ALT alanine aminotransferase
a chi-squared test
6M group (n = 642) 12M group (n = 636) Any grade, p valuea
Any grade (%) Grade ≥3 (%) Any grade (%) Grade ≥3 (%)
Hemoglobin 36.0 0.3 40.6 0.3 0.103
Leukocytes 19.2 0.6 25.6 0.3 0.007
Neutrophils 15.4 2.6 20.6 3.6 0.020
Platelets 13.7 0.5 13.7 0.5 0.839
Total bilirubin 31.2 0.5 39.2 0.8 0.003
AST 18.1 0.2 21.7 0.6 0.120
ALT 17.0 0.3 20.6 0.5 0.113
Creatinine 5.5 0 8.0 0 0.085
Anorexia 20.9 1.2 21.4 0.9 0.877
Nausea 15.6 0.5 13.7 0.6 0.379
Vomiting 6.4 0.2 5.2 0.5 0.425
Stomatitis 17.9 0.8 21.9 0.9 0.090
Diarrhea 18.1 3.0 14.9 2.0 0.152
Fatigue 15.3 1.7 16.0 1.3 0.762
Rash 10.9 0.5 10.1 0.2 0.690
Hyperpigmentation 27.9 0 25.2 0.5 0.299
Alopecia 1.9 0.2 2.5 0.2 0.550
Hand-foot syndrome 72.0 16.8 77.0 22.6 0.043
Table 7  Adverse events in the 
12M group during cycles 1–8 
and 9–16
AST aspartate aminotransferase, ALT alanine aminotransferase
During cycles 1–8 (n = 636) During cycles 9–16 (n = 417)
Any grade (%) Grade ≥3 (%) Any grade (%) Grade ≥3 (%)
Hemoglobin 34.9 0 31.7 0.5
Leukocytes 19.3 0.3 21.1 0
Neutrophils 17.6 2.8 12.9 2.2
Platelets 9.6 0.5 12.7 0
Total bilirubin 32.5 0.6 36.0 0.5
AST 16.2 0.3 17.5 0.5
ALT 15.4 0.3 14.1 0.2
Creatinine 5.2 0 7.7 0
Anorexia 18.4 0.9 9.1 0
Nausea 12.4 0.6 4.1 0
Vomiting 4.2 0.5 1.7 0
Stomatitis 18.9 0.9 10.6 0
Diarrhea 11.6 1.7 6.7 0.5
Fatigue 13.1 0.9 7.9 0.5
Rash 7.5 0.2 6.7 0
Hyperpigmentation 20.8 0.5 18.7 0
Alopecia 1.9 0 1.4 0.2
Hand-foot syndrome 71.1 19.0 66.7 8.6
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and Western patients. It was reported that oral FUs were 
less frequently associated with gastrointestinal toxicities in 
Asian patients than in Caucasian patients [11, 12]. Indeed, 
the incidences of gastrointestinal toxicities (i.e., diarrhea, 
nausea, vomiting, and stomatitis) were lower in our study 
than in the X-ACT. When compared to toxicities associ-
ated with other oral FUs (such as UFT/LV and S-1) used 
as adjuvant chemotherapy for CRC in Japan (Table 8), ano-
rexia, nausea, and diarrhea associated with capecitabine 
were less frequent [11, 12]. From these findings, we sug-
gest that capecitabine might be an easy-to-use oral FU for 
Japanese patients, when HFS is well-controlled.
HFS was the only grade ≥3 AE whose incidence 
increased with treatment during the period extending from 
6 to 12 months. Although lower in the second 6-month 
period than in the first 6-month period, the overall inci-
dence of HFS increased gradually and constantly even in 
the later period and therefore was higher in the 12M group 
than in the 6M group (Table 6).
Although the completion rate for 6-month treatment in 
our study was similar to that in other studies of adjuvant 
oral FU therapy for colon cancer [4, 5, 11–13], the comple-
tion rate for 12-month treatment was <50%. Approximately 
half of the discontinuations during cycles 9–16 was due to 
AEs, most commonly HFS. These findings indicate that 
prolonging the treatment duration resulted in a higher inci-
dence of HFS with constant cumulative onset, and that HFS 
led mainly to dose reduction and treatment discontinuation, 
but was not lethal. Therefore, effective management of HFS 
could improve the completion rate for 12-month treatment.

































Table 8  Reported incidence 
of grade ≥3 adverse events in 

























Neutropenia 2.6% 2% 1.5% 0.7%
Anorexia 1.2% <1% 3.7% 4.9%
Nausea 0.5% 3% 3.1% 1.6%
Vomiting 0.2% 1.3% 0.8%
Stomatitis 0.8% 2% -- 1.2%
Diarrhea 3.0% 11% 8.5% 4.4%
Fatigue 1.7% 1% -- 2.4%
Hand-foot syndrome 16.8% 17% 0.2% 1.3%
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The use of a hydrating cream, external steroid, and oral 
vitamin B6 is the accepted supportive treatment for HFS 
[14] and was allowed in our study. However, in this study, 
477 (74.3%) and 471 (74.5%) patients in the 6M group 
and 12M group, respectively, used oral vitamin B6. These 
recommended supportive measures should be taken in all 
cases, even at the start of the treatment.
The X-ACT trial reported that appropriate dose reduction 
does not impair the efficacy of adjuvant capecitabine ther-
apy and that the survival rate was better among those who 
developed HFS than among those who did not [15]. These 
observations suggest that appropriate dose reduction to man-
age HFS is important to maintain the treatment duration and 
to improve patient outcome. The result of the primary object 
of our study, a comparison of survival rate between the 6M 
group and 12M group, will be available in late 2016.
In conclusion, compared to the standard 6 month-treat-
ment, the cumulative incidence of HFS (the most com-
mon reason for treatment dropout) increased further after 
12 months of adjuvant capecitabine, although overall, the 
incidence and severity of AEs after 12 months of capecit-
abine were acceptable. Appropriate dose modification and 
supportive care could reduce the rate of treatment discon-
tinuation due to HFS and improve treatment compliance.
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